SCHEMBL17134622

SCHEMBL17134622

NS(=O)(=O)c1ncc(C(=O)N2CCC(c3ccc(F)cc3)CC2)c(Nc2cccc(Cl)c2)c1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR2 P34972 7/20 0.40
▸ PARP14 Q460N5 2/20 0.39
▸ TNKS O95271 1/20 0.39
▸ PARP1 P09874 1/20 0.39
▸ CNR1 P21554 4/20 0.39
▸ CYP3A4 P08684 2/20 0.39
▸ CYP2D6 P10635 2/20 0.39
▸ CYP2C9 P11712 2/20 0.39
▸ CYP2C19 P33261 2/20 0.39
▸ HSD11B1 P28845 1/20 0.39
▸ EGLN1 Q9GZT9 1/20 0.39
▸ PARP10 Q53GL7 1/20 0.39
▸ CYP1A2 P05177 1/20 0.38
▸ ABL1 P00519 1/20 0.38
▸ BCR P11274 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17134837 0.94 CNR2 (0.40) CNR2PARP14TNKSPARP1CNR1
SCHEMBL17135069 0.93 CNR2 (0.41) CNR2PARP14TNKSPARP1CNR1
SCHEMBL17135011 0.92 SPR (0.46) CNR2CNR1CYP3A4CYP2D6CYP2C9
SCHEMBL17134855 0.92 DRD4 (0.41) PARP14TNKSPARP1HSD11B1PARP10
SCHEMBL17134661 0.92 PARP14 (0.38) CNR2PARP14TNKSPARP1CNR1
SCHEMBL17135013 0.92 GRM5 (0.40) CNR2CNR1CYP3A4CYP2D6CYP2C9
SCHEMBL17134831 0.90 CCR1 (0.42) CNR1HSD11B1EGLN1PARP10LMNA
SCHEMBL17134610 0.89 EGLN1 (0.40) PARP14TNKSPARP1HSD11B1EGLN1
SCHEMBL17135034 0.89 MAPT (0.41) EGLN1MAPTNPC1
SCHEMBL17134854 0.88 MAPT (0.48) LMNAMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2927214-B1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND KYOWA HAKKO KIRIN CO LTD (JP) 2018-03-21 — — EP disclosed
US-9701689-B2 Substituted pyridines and pyridazines as CCR10 receptor inhibitors KYOWA HAKKO KIRIN CO., LTD. (JP) 2017-07-11 — — US disclosed
US-20150299214-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND KYOWA HAKKO KIRIN CO., LTD. (JP) 2015-10-22 — — US disclosed
EP-2927214-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND Kyowa Hakko Kirin Co., Ltd. (JP) 2015-10-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299214-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND ARG1, H1-0, TYR CNR2 440/4885PARP14 2224/4885TNKS 2507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback